Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05854368 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Circulating Biomarker Signatures for the Detection of Gastric Preneoplasia and Cancer

Study acronym: PREGASIGN#1
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 16, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study sites: 6 to 8
    • Primary and study completion dates: Jul 2025 to Dec 2025
    • Interventions: Additional blood collection as part of routine care (Procedure), Blood collection (Procedure) to Additional blood collection as part of a blood sampling performed during routine care or specific for the research if not part of routine…
    • Secondary endpoints: details revised at 5 of 5 entries
    v4
  2. Re-verified, no change to tracked fieldsv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: May 2025 to Jul 2025
    • Start date changed from estimate of May 2023 to Jul 3, 2023
    • Site details revised at 6 of 6 sites
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to characterize and validate a signature of circulating biomarkers in plasma, associated with the presence of gastric preneoplasia in patients with preexisting gastric lesion compared with a control group. For this purpose: * Patients with pre-existing gastric lesions will be invited to participate to this study. If they are willing to participate an additional blood sample (9 mL) will be collected at the time of the blood collection performed during their routine care * Healthy subjects will be invited to participate to constitute the control group. If they are willing to participate a blood sample (9 ml) will be drawn specifically for this study
Trial Details
NCT Number NCT05854368
Lead Sponsor Institut Pasteur
Collaborators: Assistance Publique - Hôpitaux de Paris
Conditions
(from sponsor)		 Gastric Lesion, Gastric Precancerous Condition, Gastric Cancer
Related terms Stomach Neoplasms
Enrollment 2,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov